FDA Approves New Targeted Therapy for Advanced Bile Duct Cancer

The U.S. Food and Drug Administration (FDA) has granted approval to Lyrfigtu (lirafugratinib) by Elevar Therapeutics. This marks the first selective covalent FGFR2 inhibitor for adults with previously treated unresectable, locally advanced, or metastatic bile duct cancer. This precision oncology approach addresses a significant unmet need for patients with specific FGFR2 gene alterations.